CEO Timothy Wentworth was paid $13,282,800 in fiscal year 2024, the 7th percentile of its disclosed peer group (SEC filing 0001558370-24-016214 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$13,282,800 Timothy Wentworth total, FY2024 | 7th CEO pay percentile vs peers | 705:1 CEO-to-median pay ratio | 90.32% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Timothy Wentworth | $1,290,385 | $0 | $11,600,744 | $0 | $0 | $0 | $391,671 | $13,282,800 |
| Chief Executive Officer | ||||||||
| Stefano Pessina | 0 | 0 | 7,733,836 | 0 | 0 | 0 | 135,078 | 7,868,914 |
| Executive Chairman | ||||||||
| Ornella Barra | 1,027,590 | 0 | 5,317,011 | 0 | 0 | 0 | 472,095 | 6,816,696 |
| Chief Operating Officer, International | ||||||||
| Mary Langowski | 432,373 | 2,000,000 | 4,164,307 | 0 | 0 | 0 | 56,282 | 6,652,962 |
| Executive Vice President and President, U.S. Healthcare | ||||||||
| Manmohan Mahajan | 697,000 | 1,800,000 | 2,914,313 | 0 | 0 | 0 | 125,512 | 5,536,825 |
| Global Chief Financial Officer | ||||||||
| Ginger Graham | 567,703 | 2,500,000 | 0 | 0 | 0 | 0 | 74,005 | 3,141,708 |
| Former Interim Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Timothy Wentworth | $13,282,800 | — | — | — |
| Stefano Pessina | 7,868,914 | 7,573,960 | 8,006,121 | ↑ +294,954 |
| Ornella Barra | 6,816,696 | 5,434,288 | 7,571,734 | ↑ +1,382,408 |
| Mary Langowski | 6,652,962 | — | — | — |
| Manmohan Mahajan | 5,536,825 | 1,826,108 | — | ↑ +3,710,717 |
| Ginger Graham | 3,141,708 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Walgreens Boots Alliance's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper WBA reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses WBA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named WBA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2024 total |
|---|---|---|
| Ginger Graham | CEO | $3,141,708 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| Bryan C. Hanson | Independent Director | $299,987 |
| Dominic P. Murphy | Former director (through FY2024) | $266,906 |
| Inderpal S. Bhandari | Independent Director | $300,000 |
| Janice M. Babiak | Independent Director | $432,500 |
| John A. Lederer | Independent Director | $320,000 |
| Nancy M. Schlichting | Independent Director | $469,987 |
| Robert L. Huffines | Independent Director | $59,890 |
| Stefano Pessina | Chair of the Board | — |
| Thomas E. Polen | Independent Director | $149,988 |
| Timothy C. Wentworth | Director | — |
| Valerie B. Jarrett | Independent Director | $300,000 |
| William H. Shrank, M.D | Independent Director | — |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Valerie B. Jarrett | Director | 2025-01-30 | A | 2,326.94 | $11 | $26,667 | Derivative, Class A Common | Form 4 ↗ |
| John A. Lederer | Director | 2025-01-30 | A | 2,617.8 | 11 | 30,000 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2025-01-30 | A | 2,181.5 | 11 | 25,000 | Derivative, Class A Common | Form 4 ↗ |
| Walgreens Boots Alliance, Inc. | — | 2025-02-18 | D | 12,000,000 | 21 | 253,920,000 | Common | Form 4 ↗ |
| Manmohan Mahajan | EVP and Global CFO | 2025-03-01 | D | 10,706 | 11 | 120,228 | Common | Form 4 ↗ |
| Todd Heckman | SVP, Global Controller and CAO | 2025-03-01 | D | 1,545 | 11 | 17,350 | Common | Form 4 ↗ |
| Tracey D. Brown | EVP, Pres., Walgreens Retail | 2025-03-01 | D | 1,354 | 11 | 15,205 | Common | Form 4 ↗ |
| Fabbri Beth Amber L. | Chief Corp. Affairs Officer | 2025-03-01 | D | 1,741 | 11 | 19,551 | Common | Form 4 ↗ |
| Valerie B. Jarrett | Director | 2025-04-16 | A | 2,777.78 | 11 | 30,000 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2025-04-16 | A | 2,314.82 | 11 | 25,000 | Derivative, Class A Common | Form 4 ↗ |
| John A. Lederer | Director | 2025-04-16 | A | 2,777.78 | 11 | 30,000 | Derivative, Class A Common | Form 4 ↗ |
| Stefano Pessina | Director | 2025-04-27 | D | 832,258 | 11 | 9,163,161 | Common | Form 4 ↗ |
| Stefano Pessina | Director | 2025-04-27 | A | 832,258 | 11 | 9,163,161 | Common | Form 4 ↗ |
| Mary Langowksi | EVP, President U.S. Healthcare | 2025-06-01 | D | 40,304 | 11 | 452,815 | Common | Form 4 ↗ |
| Elizabeth Burger | EVP, Global Chief HR Officer | 2025-06-01 | D | 16,495 | 11 | 185,321 | Common | Form 4 ↗ |
| Lanesha Minnix | EVP, Global CLO & Corp. Sec. | 2025-06-01 | D | 19,135 | 11 | 214,982 | Common | Form 4 ↗ |
| John A. Lederer | Director | 2025-07-09 | A | 2,590.67 | 12 | 30,000 | Derivative, Class A Common | Form 4 ↗ |
| Valerie B. Jarrett | Director | 2025-07-09 | A | 2,590.67 | 12 | 30,000 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2025-07-09 | A | 2,158.89 | 12 | 25,000 | Derivative, Class A Common | Form 4 ↗ |
| Thomas E. Polen | Director | 2025-08-13 | A | 11,774 | 0 | 0 | Common | Form 4 ↗ |
| William H. Shrank | Director | 2025-08-13 | A | 16,820.86 | 12 | 200,000 | Derivative, Class A Common | Form 4 ↗ |
| John A. Lederer | Director | 2025-08-13 | A | 16,820.86 | 12 | 200,000 | Derivative, Class A Common | Form 4 ↗ |
| Inderpal S. Bhandari | Director | 2025-08-13 | A | 16,820.86 | 12 | 200,000 | Derivative, Class A Common | Form 4 ↗ |
| Janice M. Babiak | Director | 2025-08-13 | A | 16,820.86 | 12 | 200,000 | Derivative, Class A Common | Form 4 ↗ |
| Bryan C. Hanson | Director | 2025-08-13 | A | 16,820 | 0 | 0 | Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2025-08-13 | A | 16,820.86 | 12 | 200,000 | Derivative, Class A Common | Form 4 ↗ |
| Thomas E. Polen | Director | 2025-08-13 | A | 5,046.26 | 12 | 60,000 | Derivative, Class A Common | Form 4 ↗ |
| Valerie B. Jarrett | Director | 2025-08-13 | A | 16,820.86 | 12 | 200,000 | Derivative, Class A Common | Form 4 ↗ |
| Ginger L. Graham | Director | 2025-08-13 | A | 16,820.86 | 12 | 200,000 | Derivative, Class A Common | Form 4 ↗ |
| Nancy M. Schlichting | Director | 2025-08-13 | A | 16,820 | 0 | 0 | Common | Form 4 ↗ |
| Stefano Pessina | Director | 2025-08-28 | D | 145,621,079 | 11 | 1,667,361,355 | Common | Form 4 ↗ |
| Ornella Barra | Chief Operating Officer, Int'l | 2025-08-28 | D | 139,233 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy C. Wentworth | Chief Executive Officer | 2025-08-28 | D | 1,332,014 | — | — | Common | Form 4 ↗ |
| Tracey D. Brown | EVP, Pres., Walgreens Retail | 2025-08-28 | D | 348,051 | — | — | Common | Form 4 ↗ |
| Stefano Pessina | Director | 2025-08-28 | D | 420,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stefano Pessina | Director | 2025-08-28 | D | 1,317,544 | 11 | 15,085,879 | Common | Form 4 ↗ |
| Ornella Barra | Chief Operating Officer, Int'l | 2025-08-28 | D | 1,718,000 | 11 | 19,671,100 | Common | Form 4 ↗ |
| Ornella Barra | Chief Operating Officer, Int'l | 2025-08-28 | D | 969,057 | 11 | 11,095,703 | Common | Form 4 ↗ |
| Richard P. Gates | SVP, Chief Pharmacy Officer | 2025-08-28 | D | 145,444 | — | — | Common | Form 4 ↗ |
| Elizabeth Burger | EVP, Global Chief HR Officer | 2025-08-28 | D | 303,875 | — | — | Common | Form 4 ↗ |
| Mary Langowksi | EVP, President U.S. Healthcare | 2025-08-28 | D | 494,295 | — | — | Common | Form 4 ↗ |
| Todd Heckman | SVP, Global Controller and CAO | 2025-08-28 | D | 93,037 | — | — | Common | Form 4 ↗ |
| Lanesha Minnix | EVP, Global CLO & Corp. Sec. | 2025-08-28 | D | 348,093 | — | — | Common | Form 4 ↗ |
| Manmohan Mahajan | EVP and Global CFO | 2025-08-28 | D | 414,273 | — | — | Common | Form 4 ↗ |
| Fabbri Beth Amber L. | SVP Chief Corp Affairs Officer | 2025-08-28 | D | 124,670 | — | — | Common | Form 4 ↗ |
| Stefano Pessina | Director | 2025-08-28 | D | 395,061 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stefano Pessina | Director | 2025-08-28 | D | 504,710 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stefano Pessina | Director | 2025-08-28 | D | 410,798 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stefano Pessina | Director | 2025-08-28 | D | 263,273 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ornella Barra | Chief Operating Officer, Int'l | 2025-08-28 | D | 141,806 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ornella Barra | Chief Operating Officer, Int'l | 2025-08-28 | D | 139,405 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ornella Barra | Chief Operating Officer, Int'l | 2025-08-28 | D | 133,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ornella Barra | Chief Operating Officer, Int'l | 2025-08-28 | D | 140,844 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ornella Barra | Chief Operating Officer, Int'l | 2025-08-28 | D | 84,466 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ornella Barra | Chief Operating Officer, Int'l | 2025-08-28 | D | 161,506 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ginger Graham | RSU | 1,087,528 | — | $14,550,532 |
| Ginger Graham | RSU | 238,754 | — | 6,270,381 |
| Ornella Barra | RSU | 538,628 | — | 3,058,375 |
| Ornella Barra | RSU | 359,085 | — | 954,339 |
The CLP Committee believes that the executive compensation program should reward actions and behaviors that support the Company's cultural transformation and business strategy, specifically to inspire, drive, and retain talent needed to support the consumer-centric healthcare strategy. The program aims to align the interests of senior executives with those of stockholders, reward the creation of long-term value, and drive individual accountability through both financial and non-financial goals.
| CEO STI target (% of salary) | 200% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Mercer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-01-30 | 494,137,555 | 49,908,008 | 3,039,793 | 90.32% | Passed |
| 2024 | 2024-01-25 | 518,519,997 | 77,745,201 | 3,868,821 | 86.4% | Passed |
| 2023 | 2023-01-26 | 555,423,218 | 73,571,554 | 3,954,616 | 87.75% | Passed |
| 2022 | 2022-01-27 | 390,156,161 | 240,018,027 | 4,438,721 | 61.48% | Passed |
| 2021 | 2021-01-28 | 299,571,604 | 330,495,572 | 4,665,002 | 47.2% | Failed |
| 2020 | 2020-01-30 | 559,590,843 | 109,572,606 | 6,846,624 | 82.78% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-01-30 | 90.32%a |
| 2024 | 2024-01-25 | 86.4%b |
| 2023 | 2023-01-26 | 87.75%c |
a. Approved under the standard stated in the filing — “If you elect to abstain, the abstention will have the same effect as an "AGAINST" vote on Proposal 2.”.
b. Approved under the standard stated in the filing — “If you elect to abstain, the abstention will have the same effect as an "AGAINST" vote on Proposal 3.”.
c. Approved under the standard stated in the filing — “If you elect to abstain, the abstention will have the same effect as an "AGAINST" vote on Proposal 2.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 705 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | $24,530 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Nancy M. SchlichtingIndependent · Compensation and Leadership Performance (Chair) · Audit | $270,000 | $199,987 | $0 | — | $0 | $469,987 |
| Janice M. BabiakIndependent · Audit (Chair) · Finance and Technology | 125,000 | 200,000 | 0 | — | 107,500 | 432,500 |
| Ginger L. GrahamIndependent · Lead Independent Director · Compensation and Leadership Performance | 188,571 | 166,667 | 0 | — | 0 | 355,238 |
| John A. LedererIndependent · Compensation and Leadership Performance | 120,000 | 200,000 | 0 | — | 0 | 320,000 |
| Inderpal S. BhandariIndependent · Audit · Finance and Technology · Nominating and Governance | 100,000 | 200,000 | 0 | — | 0 | 300,000 |
| Valerie B. JarrettIndependent · Audit · Compensation and Leadership Performance | 100,000 | 200,000 | 0 | — | 0 | 300,000 |
| Bryan C. HansonIndependent · Compensation and Leadership Performance | 100,000 | 199,987 | 0 | — | 0 | 299,987 |
| Dominic P. MurphyIndependent · Not standing for re-election · Departed during FY | 66,906 | 200,000 | 0 | — | 0 | 266,906 |
| Thomas E. PolenIndependent · Finance and Technology | 100,000 | 49,988 | 0 | — | 0 | 149,988 |
| Robert L. HuffinesIndependent · Finance and Technology · Newly elected | 59,890 | 0 | 0 | — | 0 | 59,890 |
| Timothy C. WentworthEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| William H. Shrank, M.DIndependent · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Stefano PessinaEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $100,000 |
|---|---|
| Annual equity retainer | $200,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 20,000 |
| Stock ownership guideline | $3 |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $1,230,367 |
| Equity awards (grant-date value) | $1,616,629 |
| All other compensation | $107,500 |
| Total cost of the board | $2,954,496 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Walgreens Boots Alliance names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Walgreens Boots Alliance.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 2025 | Joaquin Duato | $1,600,000 | $15,028,948 | $5,927,995 | $4,298,700 | $32,758,111 |
| 2 | Coca-Cola | 2025 | James Quincey | 1,675,000 | 12,516,109 | 10,352,255 | 5,025,000 | 31,208,165 |
| 3 | Pfizer | 2025 | Albert Bourla | 1,800,000 | 9,442,705 | 8,998,141 | 5,400,000 | 27,585,301 |
| 4 | Mondelez | 2025 | Dirk Van de Put | 1,624,615 | 14,530,359 | 4,401,555 | 3,234,000 | 24,516,114 |
| 5 | McKesson | 2026 | Brian Tyler | 1,591,667 | 17,201,202 | 0 | 4,456,668 | 24,213,044 |
| 6 | PepsiCo | 2025 | Ramon Laguarta | 1,804,615 | 11,550,008 | 0 | 5,771,000 | 23,903,545 |
| 7 | Medtronic | 2026 | Geoffrey Martha | 1,399,039 | 13,672,200 | 5,175,559 | 2,307,200 | 22,940,252 |
| 8 | Cigna | 2025 | David Cordani | 1,600,000 | 13,929,161 | 3,400,019 | 3,200,000 | 22,866,134 |
| 9 | CVS Health | 2025 | J. David Joyner | 1,500,000 | 14,499,931 | 0 | 4,695,900 | 21,214,084 |
| 10 | McDonald's | 2025 | Christopher Kempczinski | 1,550,000 | 8,000,215 | 8,000,066 | 2,367,160 | 20,574,525 |
| 11 | Procter & Gamble | 2026 | Shailesh Jejurikar | 1,387,500 | 11,035,209 | 3,500,010 | 0 | 18,976,742 |
| 12 | Humana | 2025 | James Rechtin | 1,348,558 | 13,868,141 | 0 | 3,034,740 | 18,757,075 |
| 13 | Kroger | 2025 | Ronald L. Sargent | 3,975,806 | 10,000,077 | — | — | 14,037,608 |
| 14 | Costco | 2025 | Ron Vachris | 1,183,270 | 12,036,800 | 0 | 600,000 | 13,932,597 |
| 15 | Walgreens Boots Alliance | 2024 | Timothy Wentworth | 1,290,385 | 11,600,744 | 0 | 0 | 13,282,800 |
| 16 | Target | 2025 | Michael Fiddelke | 1,065,385 | 7,853,253 | 0 | 300,882 | 9,598,071 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Walgreens Boots Alliance | not disclosed | RSU 100 | not disclosed | Mercer |
| Cigna | 100% | PSU 60 · RSU 20 · Options 20 | No | Pay Governance |
| Coca-Cola | 150% | PSU 50 · Options 50 | Yes — Relative TSR modifier | Meridian Compensation Partners, LLC |
| Costco | 120% | RSU 100 | No | None used (Committee has authority to engage consultants but did not use any) |
| CVS Health | 156.5% | PSU 60 · RSU 20 · Options 20 | Yes — rTSR Modifier | Korn Ferry |
| Humana | 112% | PSU 60 · RSU 40 | Yes — Relative TSR | Farient Advisors, LLC |
| Johnson & Johnson | not disclosed | not disclosed | Yes — Relative TSR | Semler Brossy Consulting Group |
| Kroger | 93.84% | not disclosed | Yes — Value creation (iTSR) | Korn Ferry; Meridian Compensation Partners, LLC |
| McDonald's | not disclosed | PRSU 50 · Option 50 | No | Semler Brossy Consulting Group LLC |
| McKesson | 140% | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) relative to comparator group | Korn Ferry |
| Medtronic | 103% | PSU 50 · Options 30 · RSU 20 | No | Semler Brossy |
| Mondelez | 91% | PSU 75 · Options 25 | No | not disclosed |
| PepsiCo | not disclosed | not disclosed | Yes — Relative TSR Performance | FW Cook |
| Pfizer | 150% | PSU 50 · MSU 50 | Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG) | Meridian Compensation Partners, LLC |
| Procter & Gamble | not disclosed | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR Multiplier | Meridian Compensation Partners, LLC |
| Target | not disclosed | PSU 60 · PBRSU 40 | No | Semler Brossy |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Timothy Wentworth | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Executive Compensation Tables and Supporting Information” · page 73. As printed: 13,282,800. Filing ↗machine: r11 · c18 · span 2265448–2265458 |
| 2 | Section 01, Stefano Pessina | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Executive Compensation Tables and Supporting Information” · page 73. As printed: 7,868,914. Filing ↗machine: r8 · c18 · span 2247796–2247805 |
| 3 | Section 01, Ornella Barra | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Executive Compensation Tables and Supporting Information” · page 73. As printed: 6,816,696. Filing ↗machine: r17 · c18 · span 2301763–2301772 |
| 4 | Section 01, Mary Langowski | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Executive Compensation Tables and Supporting Information” · page 73. As printed: 6,652,962. Filing ↗machine: r20 · c18 · span 2319338–2319347 |
| 5 | Section 01, Manmohan Mahajan | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Executive Compensation Tables and Supporting Information” · page 73. As printed: 5,536,825. Filing ↗machine: r14 · c18 · span 2283464–2283473 |
| 6 | Section 01, Ginger Graham | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Executive Compensation Tables and Supporting Information” · page 73. As printed: 3,141,708. Filing ↗machine: r24 · c18 · span 2342384–2342393 |
| 7 | Section 07, pay ratio | DEF 14A | 2022-12-08 | 0001308179-22-000390 | Section “CEO Pay Ratio”. As printed: 705 : 1. Filing ↗machine: span 1392836–1392839 |
| 8 | Section 08, Nancy M. Schlichting | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 469,987. Filing ↗machine: span 1474436–1474627 |
| 9 | Section 08, Janice M. Babiak | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 432,500. Filing ↗machine: span 1448602–1448793 |
| 10 | Section 08, Ginger L. Graham | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 355,238. Filing ↗machine: span 1454298–1454489 |
| 11 | Section 08, John A. Lederer | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 320,000. Filing ↗machine: span 1465780–1465971 |
| 12 | Section 08, Inderpal S. Bhandari | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 300,000. Filing ↗machine: span 1451452–1451643 |
| 13 | Section 08, Valerie B. Jarrett | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 300,000. Filing ↗machine: span 1462935–1463126 |
| 14 | Section 08, Bryan C. Hanson | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 299,987. Filing ↗machine: span 1457143–1457334 |
| 15 | Section 08, Dominic P. Murphy | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 266,906. Filing ↗machine: span 1468724–1468915 |
| 16 | Section 08, Thomas E. Polen | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 149,988. Filing ↗machine: span 1471568–1471759 |
| 17 | Section 08, Robert L. Huffines | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 59,890. Filing ↗machine: span 1458196–1458386 |
| 18 | Section 08, Timothy C. Wentworth | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 19 | Section 08, William H. Shrank, M.D | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 20 | Section 08, Stefano Pessina | DEF 14A | 2024-12-13 | 0001558370-24-016214 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 21 | Section 02, Valerie B. Jarrett 2025-01-30 | Form 4 | 2025-02-03 | 0001618921-25-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, John A. Lederer 2025-01-30 | Form 4 | 2025-02-03 | 0001618921-25-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Robert L. Huffines 2025-01-30 | Form 4 | 2025-02-03 | 0001618921-25-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Walgreens Boots Alliance, Inc. 2025-02-18 | Form 4 | 2025-02-20 | 0000950170-25-024214 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Manmohan Mahajan 2025-03-01 | Form 4 | 2025-03-04 | 0001618921-25-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Todd Heckman 2025-03-01 | Form 4 | 2025-03-04 | 0001618921-25-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Tracey D. Brown 2025-03-01 | Form 4 | 2025-03-04 | 0001618921-25-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Fabbri Beth Amber L. 2025-03-01 | Form 4 | 2025-03-04 | 0001618921-25-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Valerie B. Jarrett 2025-04-16 | Form 4 | 2025-04-18 | 0001618921-25-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Robert L. Huffines 2025-04-16 | Form 4 | 2025-04-18 | 0001618921-25-000042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, John A. Lederer 2025-04-16 | Form 4 | 2025-04-18 | 0001618921-25-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Stefano Pessina 2025-04-27 | Form 4 | 2025-04-29 | 0001554687-25-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Stefano Pessina 2025-04-27 | Form 4 | 2025-04-29 | 0001554687-25-000001 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Mary Langowksi 2025-06-01 | Form 4 | 2025-06-03 | 0001618921-25-000048 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Elizabeth Burger 2025-06-01 | Form 4 | 2025-06-03 | 0001618921-25-000047 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Lanesha Minnix 2025-06-01 | Form 4 | 2025-06-03 | 0001618921-25-000050 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, John A. Lederer 2025-07-09 | Form 4 | 2025-07-11 | 0001618921-25-000060 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Valerie B. Jarrett 2025-07-09 | Form 4 | 2025-07-11 | 0001618921-25-000062 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Robert L. Huffines 2025-07-09 | Form 4 | 2025-07-11 | 0001618921-25-000063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Thomas E. Polen 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, William H. Shrank 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000080 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, John A. Lederer 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000084 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Inderpal S. Bhandari 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Janice M. Babiak 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000090 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Bryan C. Hanson 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000088 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Robert L. Huffines 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000094 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Thomas E. Polen 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000082 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Valerie B. Jarrett 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Ginger L. Graham 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Nancy M. Schlichting 2025-08-13 | Form 4 | 2025-08-15 | 0001618921-25-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Stefano Pessina 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111882 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Ornella Barra 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Timothy C. Wentworth 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111920 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Tracey D. Brown 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111907 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Stefano Pessina 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111882 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Stefano Pessina 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111882 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Ornella Barra 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Ornella Barra 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Richard P. Gates 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111906 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Elizabeth Burger 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111911 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Mary Langowksi 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111917 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Todd Heckman 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111919 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Lanesha Minnix 2025-08-28 | Form 4 | 2025-08-28 | 0001193125-25-191100 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Manmohan Mahajan 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Fabbri Beth Amber L. 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Stefano Pessina 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111882 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Stefano Pessina 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111882 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Stefano Pessina 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111882 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Stefano Pessina 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111882 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Ornella Barra 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Ornella Barra 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Ornella Barra 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Ornella Barra 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Ornella Barra 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Ornella Barra 2025-08-28 | Form 4 | 2025-08-28 | 0000950170-25-111883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 06, 2025 vote | Form 8-K | 2025-02-05 | 0001193125-25-020848 | Item 5.07 · say-on-pay result. As reported: 90.32% (votes for as printed: 494,137,555). Filing ↗ |
| 77 | Section 06, 2024 vote | Form 8-K | 2024-01-31 | 0001193125-24-021052 | Item 5.07 · say-on-pay result. As reported: 86.4% (votes for as printed: 518,519,997). Filing ↗ |
| 78 | Section 06, 2023 vote | Form 8-K | 2023-01-31 | 0001193125-23-020487 | Item 5.07 · say-on-pay result. As reported: 87.75% (votes for as printed: 555,423,218). Filing ↗ |
| 79 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 80 | Section 09b board cost (computed) | Computed | — | — | Cash 1,230,367 + equity 1,616,629 + all other 107,500 = 2,954,496, summed across the director compensation table rows.machine: formula: Σ = 2,954,496 |
| 81 | Johnson & Johnson, Section 10b CEO total | DEF 14A | 2026-03-11 | 0000200406-26-000063 | CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246 |
| 82 | Coca-Cola, Section 10b CEO total | DEF 14A | 2026-03-16 | 0001104659-26-028215 | CEO total compensation as printed in Coca-Cola's own proxy. As printed: 31,208,165. Filing ↗machine: t286 · r11 · c26 · span 3291227–3291237 |
| 83 | Pfizer, Section 10b CEO total | DEF 14A | 2026-03-12 | 0000078003-26-000033 | CEO total compensation as printed in Pfizer's own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835 |
| 84 | Mondelez, Section 10b CEO total | DEF 14A | 2026-04-03 | 0001628280-26-023640 | CEO total compensation as printed in Mondelez's own proxy. As printed: 24,516,114. Filing ↗machine: r2 · c9 · span 2504218–2504228 |
| 85 | McKesson, Section 10b CEO total | DEF 14A | 2026-06-12 | 0000927653-26-000169 | CEO total compensation as printed in McKesson's own proxy. As printed: 24,213,044. Filing ↗machine: r2 · c21 · span 1260172–1260182 |
| 86 | PepsiCo, Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000169 | CEO total compensation as printed in PepsiCo's own proxy. As printed: 23,903,545. Filing ↗machine: r2 · c20 · span 826280–826290 |
| 87 | Medtronic, Section 10b CEO total | DEF 14A | 2026-08-17 | 0001613103-26-000010 | CEO total compensation as printed in Medtronic's own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230 |
| 88 | Cigna, Section 10b CEO total | DEF 14A | 2026-03-13 | 0001739940-26-000023 | CEO total compensation as printed in Cigna's own proxy. As printed: 22,866,134. Filing ↗machine: t303 · r3 · c16 · span 1360729–1360739 |
| 89 | CVS Health, Section 10b CEO total | DEF 14A | 2026-04-03 | 0001308179-26-000201 | CEO total compensation as printed in CVS Health's own proxy. As printed: 21,214,084. Filing ↗machine: r1 · c18 · span 969864–969874 |
| 90 | McDonald's, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-145548 | CEO total compensation as printed in McDonald's's own proxy. As printed: 20,574,525. Filing ↗machine: r4 · c25 · span 2683025–2683035 |
| 91 | Procter & Gamble, Section 10b CEO total | DEF 14A | 2026-08-28 | 0001193125-26-372211 | CEO total compensation as printed in Procter & Gamble's own proxy. As printed: 18,976,742. Filing ↗ |
| 92 | Humana, Section 10b CEO total | DEF 14A | 2026-03-06 | 0001104659-26-024799 | CEO total compensation as printed in Humana's own proxy. As printed: 18,757,075. Filing ↗machine: t157 · r1 · c63 · span 1938706–1938716 |
| 93 | Kroger, Section 10b CEO total | DEF 14A | 2026-05-13 | 0001104659-26-060250 | CEO total compensation as printed in Kroger's own proxy. As printed: 14,037,608. Filing ↗machine: t229 · r1 · c9 · span 692555–692565 |
| 94 | Costco, Section 10b CEO total | DEF 14A | 2025-12-04 | 0000909832-25-000159 | CEO total compensation as printed in Costco's own proxy. As printed: 13,932,597. Filing ↗machine: r2 · c48 · span 281465–281475 |
| 95 | Walgreens Boots Alliance (subject), Section 10b CEO total | DEF 14A | 2024-12-13 | 0001558370-24-016214 | CEO total compensation as printed in Walgreens Boots Alliance's own proxy. As printed: 13,282,800. Filing ↗machine: r11 · c18 · span 2265448–2265458 |
| 96 | Target, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027508 | CEO total compensation as printed in Target's own proxy. As printed: 9,598,071. Filing ↗machine: r7 · c8 · span 2799507–2799517 |
| 97 | Section 10a, Humana reciprocity | DEF 14A | — | 0001104659-26-024799 | Humana names Walgreens Boots Alliance in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 98 | Section 10a, Johnson & Johnson reciprocity | DEF 14A | — | 0000200406-26-000063 | Johnson & Johnson's most recent proxy was read; its disclosed peer group does not include Walgreens Boots Alliance. Filing ↗ |
| 99 | Section 10a, Costco reciprocity | DEF 14A | — | 0000909832-25-000159 | Costco's most recent proxy was read; its disclosed peer group does not include Walgreens Boots Alliance. Filing ↗ |
| 100 | Section 10a, Procter & Gamble reciprocity | DEF 14A | — | 0001193125-26-372211 | Procter & Gamble's most recent proxy was read; its disclosed peer group does not include Walgreens Boots Alliance. Filing ↗ |
| 101 | Section 10a, Coca-Cola reciprocity | DEF 14A | — | 0001104659-26-028215 | Coca-Cola's most recent proxy was read; its disclosed peer group does not include Walgreens Boots Alliance. Filing ↗ |
| 102 | Section 10a, Pfizer reciprocity | DEF 14A | — | 0000078003-26-000033 | Pfizer's most recent proxy was read; its disclosed peer group does not include Walgreens Boots Alliance. Filing ↗ |
| 103 | Section 10a, McKesson reciprocity | DEF 14A | — | 0000927653-26-000169 | McKesson's most recent proxy was read; its disclosed peer group does not include Walgreens Boots Alliance. Filing ↗ |
| 104 | Section 10a, Cigna reciprocity | DEF 14A | — | 0001739940-26-000023 | Cigna names Walgreens Boots Alliance in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 105 | Section 10a, Target reciprocity | DEF 14A | — | 0001628280-26-027508 | Target's most recent proxy was read; its disclosed peer group does not include Walgreens Boots Alliance. Filing ↗ |
| 106 | Section 10a, Mondelez reciprocity | DEF 14A | — | 0001628280-26-023640 | Mondelez's most recent proxy was read; its disclosed peer group does not include Walgreens Boots Alliance. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.